Details for New Drug Application (NDA): 213977
✉ Email this page to a colleague
NDA 213977 describes ONSURA, which is a drug marketed by Teva Pharms Usa and is included in one NDA. Additional details are available on the ONSURA profile page.
The generic ingredient in ONSURA is ethinyl estradiol; norelgestromin. There are twenty-six drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the ethinyl estradiol; norelgestromin profile page.
The generic ingredient in ONSURA is ethinyl estradiol; norelgestromin. There are twenty-six drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the ethinyl estradiol; norelgestromin profile page.
Summary for 213977
| Tradename: | ONSURA |
| Applicant: | Teva Pharms Usa |
| Ingredient: | ethinyl estradiol; norelgestromin |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | FILM, EXTENDED RELEASE;TRANSDERMAL | Strength | 0.035MG/24HR;0.15MG/24HR | ||||
| Approval Date: | Aug 25, 2021 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
